Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to...
top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Oct 21
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
JERUSALEM, October 21, 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Oct 10
Alpha Tau Treats First Patient with Recurrent Lung Cancer
first patient with recurrent lung cancer has been treated, in a clinical trial at Hadassah Medical Center in Jerusalem, Israel.
Sep 20
FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this...
Aug 22
Alpha Tau to Participate in multiple upcoming investor conferences
JERUSALEM, August 2 2 , 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 14
Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term...
Jun 25
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin,...
May 22
Alpha Tau to Present at the Jefferies Global Healthcare Conference
JERUSALEM, May 21, 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 21
Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - -...
May 13
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
JERUSALEM, May 13, 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
bottom of page